BACKGROUND: Temozolomide (TMZ) is one of the most potent chemotherapy agents for the treatment of glioblastoma. Unfortunately, almost half of glioblastoma tumors are TMZ resistant due to overexpression of methylguanine methyltransferase (MGMT(hi)). Coadministration of O6-benzylguanine (O6BG) can restore TMZ sensitivity, but causes off-target myelosuppression. Here, we conducted a prospective clinical trial to test whether gene therapy to confer O6BG resistance in hematopoietic stem cells (HSCs) improves chemotherapy tolerance and outcome. METHODS: We enrolled 7 newly diagnosed glioblastoma patients with MGMT(hi) tumors. Patients received autologous gene-modified HSCs following single-agent carmustine administration. After hematopoietic recovery, patients underwent O6BG/TMZ chemotherapy in 28-day cycles. Serial blood samples and tumor images were collected throughout the study. Chemotherapy tolerance was determined by the observed myelosuppression and recovery following each cycle. Patient-specific biomathematical modeling of tumor growth was performed. Progression-free survival (PFS) and overall survival (OS) were also evaluated. RESULTS: Gene therapy permitted a significant increase in the mean number of tolerated O6BG/TMZ cycles (4.4 cycles per patient, P < 0.05) compared with historical controls without gene therapy (n = 7 patients, 1.7 cycles per patient). One patient tolerated an unprecedented 9 cycles and demonstrated long-term PFS without additional therapy. Overall, we observed a median PFS of 9 (range 3.5-57+) months and OS of 20 (range 13-57+) months. Furthermore, biomathematical modeling revealed markedly delayed tumor growth at lower cumulative TMZ doses in study patients compared with patients that received standard TMZ regimens without O6BG. CONCLUSION: These data support further development of chemoprotective gene therapy in combination with O6BG and TMZ for the treatment of glioblastoma and potentially other tumors with overexpression of MGMT. TRIAL REGISTRATION: Clinicaltrials.gov NCT00669669. FUNDING: R01CA114218, R01AI080326, R01HL098489, P30DK056465, K01DK076973, R01HL074162, R01CA164371, R01NS060752, U54CA143970.
BACKGROUND:Temozolomide (TMZ) is one of the most potent chemotherapy agents for the treatment of glioblastoma. Unfortunately, almost half of glioblastoma tumors are TMZ resistant due to overexpression of methylguanine methyltransferase (MGMT(hi)). Coadministration of O6-benzylguanine (O6BG) can restore TMZ sensitivity, but causes off-target myelosuppression. Here, we conducted a prospective clinical trial to test whether gene therapy to confer O6BG resistance in hematopoietic stem cells (HSCs) improves chemotherapy tolerance and outcome. METHODS: We enrolled 7 newly diagnosed glioblastomapatients with MGMT(hi) tumors. Patients received autologous gene-modified HSCs following single-agent carmustine administration. After hematopoietic recovery, patients underwent O6BG/TMZ chemotherapy in 28-day cycles. Serial blood samples and tumor images were collected throughout the study. Chemotherapy tolerance was determined by the observed myelosuppression and recovery following each cycle. Patient-specific biomathematical modeling of tumor growth was performed. Progression-free survival (PFS) and overall survival (OS) were also evaluated. RESULTS: Gene therapy permitted a significant increase in the mean number of tolerated O6BG/TMZ cycles (4.4 cycles per patient, P < 0.05) compared with historical controls without gene therapy (n = 7 patients, 1.7 cycles per patient). One patient tolerated an unprecedented 9 cycles and demonstrated long-term PFS without additional therapy. Overall, we observed a median PFS of 9 (range 3.5-57+) months and OS of 20 (range 13-57+) months. Furthermore, biomathematical modeling revealed markedly delayed tumor growth at lower cumulative TMZ doses in study patients compared with patients that received standard TMZ regimens without O6BG. CONCLUSION: These data support further development of chemoprotective gene therapy in combination with O6BG and TMZ for the treatment of glioblastoma and potentially other tumors with overexpression of MGMT. TRIAL REGISTRATION: Clinicaltrials.gov NCT00669669. FUNDING: R01CA114218, R01AI080326, R01HL098489, P30DK056465, K01DK076973, R01HL074162, R01CA164371, R01NS060752, U54CA143970.
Authors: Patrick Y Wen; David R Macdonald; David A Reardon; Timothy F Cloughesy; A Gregory Sorensen; Evanthia Galanis; John Degroot; Wolfgang Wick; Mark R Gilbert; Andrew B Lassman; Christina Tsien; Tom Mikkelsen; Eric T Wong; Marc C Chamberlain; Roger Stupp; Kathleen R Lamborn; Michael A Vogelbaum; Martin J van den Bent; Susan M Chang Journal: J Clin Oncol Date: 2010-03-15 Impact factor: 44.544
Authors: Jennifer E Adair; Brian C Beard; Grant D Trobridge; Tobias Neff; Jason K Rockhill; Daniel L Silbergeld; Maciej M Mrugala; Hans-Peter Kiem Journal: Sci Transl Med Date: 2012-05-09 Impact factor: 17.956
Authors: R Rockne; J K Rockhill; M Mrugala; A M Spence; I Kalet; K Hendrickson; A Lai; T Cloughesy; E C Alvord; K R Swanson Journal: Phys Med Biol Date: 2010-05-18 Impact factor: 3.609
Authors: Jing Li; Meihua Wang; Minhee Won; Edward G Shaw; Christopher Coughlin; Walter J Curran; Minesh P Mehta Journal: Int J Radiat Oncol Biol Phys Date: 2010-10-01 Impact factor: 7.038
Authors: Brian C Beard; Grant D Trobridge; Christina Ironside; Jeannine S McCune; Jennifer E Adair; Hans-Peter Kiem Journal: J Clin Invest Date: 2010-06-14 Impact factor: 14.808
Authors: Christina H Wang; Jason K Rockhill; Maciej Mrugala; Danielle L Peacock; Albert Lai; Katy Jusenius; Joanna M Wardlaw; Timothy Cloughesy; Alexander M Spence; Russ Rockne; Ellsworth C Alvord; Kristin R Swanson Journal: Cancer Res Date: 2009-11-24 Impact factor: 12.701
Authors: Maxwell Lewis Neal; Andrew D Trister; Sunyoung Ahn; Anne Baldock; Carly A Bridge; Laura Guyman; Jordan Lange; Rita Sodt; Tyler Cloke; Albert Lai; Timothy F Cloughesy; Maciej M Mrugala; Jason K Rockhill; Russell C Rockne; Kristin R Swanson Journal: Cancer Res Date: 2013-02-11 Impact factor: 12.701
Authors: Shota Tanaka; David N Louis; William T Curry; Tracy T Batchelor; Jorg Dietrich Journal: Nat Rev Clin Oncol Date: 2012-11-27 Impact factor: 66.675
Authors: Maxwell Lewis Neal; Andrew D Trister; Tyler Cloke; Rita Sodt; Sunyoung Ahn; Anne L Baldock; Carly A Bridge; Albert Lai; Timothy F Cloughesy; Maciej M Mrugala; Jason K Rockhill; Russell C Rockne; Kristin R Swanson Journal: PLoS One Date: 2013-01-23 Impact factor: 3.240
Authors: Jennifer L Gori; Jason M Butler; Yan-Yi Chan; Devikha Chandrasekaran; Michael G Poulos; Michael Ginsberg; Daniel J Nolan; Olivier Elemento; Brent L Wood; Jennifer E Adair; Shahin Rafii; Hans-Peter Kiem Journal: J Clin Invest Date: 2015-02-09 Impact factor: 14.808
Authors: N Lachmann; K Czarnecki; S Brennig; R Phaltane; M Heise; N Heinz; H Kempf; D Dilloo; V Kaever; A Schambach; M Heuser; T Moritz Journal: Leukemia Date: 2015-04-29 Impact factor: 11.528
Authors: Corbin A Rayfield; Fillan Grady; Gustavo De Leon; Russell Rockne; Eduardo Carrasco; Pamela Jackson; Mayur Vora; Sandra K Johnston; Andrea Hawkins-Daarud; Kamala R Clark-Swanson; Scott Whitmire; Mauricio E Gamez; Alyx Porter; Leland Hu; Luis Gonzalez-Cuyar; Bernard Bendok; Sujay Vora; Kristin R Swanson Journal: JCO Clin Cancer Inform Date: 2018-12
Authors: Katie Storey; Kevin Leder; Andrea Hawkins-Daarud; Kristin Swanson; Atique U Ahmed; Russell C Rockne; Jasmine Foo Journal: JCO Clin Cancer Inform Date: 2019-02
Authors: Olivier Humbert; Frieda Chan; Yogendra S Rajawat; Troy R Torgerson; Christopher R Burtner; Nicholas W Hubbard; Daniel Humphrys; Zachary K Norgaard; Patricia O'Donnell; Jennifer E Adair; Grant D Trobridge; Andrew M Scharenberg; Peter J Felsburg; David J Rawlings; Hans-Peter Kiem Journal: Blood Adv Date: 2018-05-08